Madan Jagasia
Faculty Member
Last active: 3/20/2014

  1. Genetic variation in donor CTLA-4 regulatory region is a strong predictor of outcome after allogeneic hematopoietic cell transplantation for hematologic malignancies. Jagasia M, Clark WB, Brown-Gentry KD, Crawford DC, Fan KH, Chen H, Kassim A, Greer JP, Engelhardt BG, Savani BN (2012) Biol Blood Marrow Transplant 18(7): 1069-75
    › Primary publication · 22178694 (PubMed)
  2. Endocrine complications in long-term survivors after allogeneic stem cell transplant. Gunasekaran U, Agarwal N, Jagasia MH, Jagasia SM (2012) Semin Hematol 49(1): 66-72
    › Primary publication · 22221786 (PubMed)
  3. Consolidative therapy with stem cell transplantation improves survival of patients with mantle cell lymphoma after any induction regimen. Reddy N, Greer JP, Goodman S, Kassim A, Morgan DS, Chinratanalab W, Brandt S, Englehardt B, Oluwole O, Jagasia MH, Savani BN (2012) Exp Hematol 40(5): 359-66
    › Primary publication · 22269117 (PubMed) · PMC4845757 (PubMed Central)
  4. Allo-SCT for high-risk AML-CR1 in the molecular era: impact of FLT3/ITD outweighs the conventional markers. Sengsayadeth SM, Jagasia M, Engelhardt BG, Kassim A, Strickland SA, Goodman S, Lucid C, Vnencak-Jones CL, Greer JP, Savani BN (2012) Bone Marrow Transplant 47(12): 1535-7
    › Primary publication · 22659680 (PubMed)
  5. Quantitative assessment of myeloid nuclear differentiation antigen distinguishes myelodysplastic syndrome from normal bone marrow. McClintock-Treep SA, Briggs RC, Shults KE, Flye-Blakemore LA, Mosse CA, Jagasia MH, Shinar AA, Dupont WD, Stelzer GT, Head DR (2011) Am J Clin Pathol 135(3): 380-5
    › Primary publication · 21350091 (PubMed)
  6. Innovative analyses support a role for DNA damage and an aberrant cell cycle in myelodysplastic syndrome pathogenesis. Head DR, Jacobberger JW, Mosse C, Jagasia M, Dupont W, Goodman S, Flye L, Shinar A, McClintock-Treep S, Stelzer G, Briggs R, Shults K (2011) Bone Marrow Res : 950934
    › Primary publication · 22046573 (PubMed) · PMC3200066 (PubMed Central)
  7. Genetic variation in recipient B-cell activating factor modulates phenotype of GVHD. Clark WB, Brown-Gentry KD, Crawford DC, Fan KH, Snavely J, Chen H, Savani BN, Kassim A, Greer JP, Schuening FG, Engelhardt BG, Jagasia MH (2011) Blood 118(4): 1140-4
    › Primary publication · 21628416 (PubMed)
  8. Progressive multifocal leukoencephalopathy in a patient with follicular lymphoma treated with multiple courses of rituximab. Reddy N, Abel TW, Jagasia M, Morgan D, Weaver K, Greer J (2009) Leuk Lymphoma 50(3): 460-2
    › Primary publication · 19266387 (PubMed)
  9. Pathology of graft-versus-host disease in the gastrointestinal tract. Washington K, Jagasia M (2009) Hum Pathol 40(7): 909-17
    › Primary publication · 19524102 (PubMed)
  10. Classic and overlap chronic graft-versus-host disease (cGVHD) is associated with superior outcome after extracorporeal photopheresis (ECP). Jagasia MH, Savani BN, Stricklin G, Engelhardt B, Kassim A, Dixon S, Chen H, Chinratanalab W, Goodman S, Greer JP, Schuening F (2009) Biol Blood Marrow Transplant 15(10): 1288-95
    › Primary publication · 19747637 (PubMed) · PMC3159406 (PubMed Central)